Видео ютуба по тегу Vemurafenib

Combination therapies with vemurafenib in BRAF v600E–mutant cancers
Combination therapies with vemurafenib in BRAF v600E–mutant cancers
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma
Vemurafenib and cobimetinib in patients with BRAF-mutated melanoma
Expert Discusses the Safety of Vemurafenib
Expert Discusses the Safety of Vemurafenib
Vemurafenib for high risk melanoma patients
Vemurafenib for high risk melanoma patients
Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma
Dr. Omid Hamid on Vemurafenib and Atezolizumab in Melanoma
BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD
BRAF Targeted Therapy - Melanoma Education Symposium, Peter Boasberg MD
Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL
Dr. Tiacci on Vemurafenib/Rituximab Combo in HCL
Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia
Phase II Evaluates Vemurafenib/Obinutuzumab in Hairy Cell Leukemia
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
Vemurafenib in patients with BRAF600 mutation–positive metastatic melanoma
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutat...
IMspire 150: Atezolizumab, cobimetinib and vemurafenib in untreated patients with BRAFV600 mutat...
Dr. Chapman Describes the Vemurafenib Clinical Trial
Dr. Chapman Describes the Vemurafenib Clinical Trial
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma
Cobimetinib plus vemurafenib for advanced BRAF-mutated melanoma
Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma
Dr. Weber on Dabrafenib/Trametinib Versus Vemurafenib/Cobimetinib in Melanoma
BRIM8: Vemurafenib in high risk melanoma patients
BRIM8: Vemurafenib in high risk melanoma patients
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-m...
COLUMBUS: Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-m...
Regulatory Approvals for Vemurafenib/Cobimetinib, Necitumumab, and Elotuzumab
Regulatory Approvals for Vemurafenib/Cobimetinib, Necitumumab, and Elotuzumab
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma
Vemurafenib plus cobimetinib achieves significant progression-free survival in melanoma